Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Panbela Therapeutics, Inc. - Common Stock (NQ: PBLA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 1.020 (5)
Ask (Size) 1.040 (1)
Prev. Close 1.110
Today's Range N/A - N/A
52wk Range 1.060 - 11.00
Shares Outstanding 5,127,686
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q1 2024
PBLA stock results show that Panbela Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
Developed in collaboration with Sanofi. 
From Panbela Therapeutics, Inc.
Via GlobeNewswire

Performance

More News

Read More
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Recap: Panbela Therapeutics Q4 Earnings
Via Benzinga
Earnings Preview: Panbela Therapeutics
Via Benzinga
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Poster Presentation at American Association for Cancer Research:
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Transfer to OTCQB Market
From Panbela Therapeutics, Inc.
Via GlobeNewswire
PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Top 4 Health Care Stocks That Are Preparing To Pump This Month
Via Benzinga
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
From Panbela Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
BioMedNewsBreaks – Panbela Therapeutics Inc. (NASDAQ: PBLA) Secures ~$9M in Public Offering
Via Investor Brand Network
Panbela Announces Closing of Approximately $9.0 Million Public Offering
From Panbela Therapeutics, Inc.
Via GlobeNewswire
What's Going On With Panbela Therapeutics Stock Today?
Via Benzinga
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Crude Oil Down Over 1%; Science 37 Holdings Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Panbela Therapeutics Shares Are Trading Lower By 65%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Edges Lower; Cardlytics Shares Jump
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Edge Higher; Amazon And iRobot Agree To Terminate Acquisition Deal
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Aclarion (ACON) Stock Down 16% Today?
Via InvestorPlace
Why Is Panbela Therapeutics (PBLA) Stock Down 63% Today?
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.